Evidence map›Paper›PMID 39697732›Full record

ReviewTranslational cancer research2024

Targeting breast cancer resistance protein (BCRP/ABCG2) in cancer.

Rouan Chen, Yue Yu, Ruixin Liu, Qian Chen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Extracellular vesicle-mediated chemoresistance in breast cancer: focus on miRNA cargo.Extracellular vesicles and circulating nucleic acids · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rouan ChenMedical College of Ophthalmology and Optometry, Shandong University of Traditional Chinese Medicine, Jinan, China.
Yue YuCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Ruixin LiuCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Qian ChenDepartment of Pathology, Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is one of the most common cancers among women. Nowadays postoperative adjuvant chemotherapy is the mainstay for clinical treatment of breast cancer. However, the emergence of multidrug resistance (MDR) in breast cancer has become a main reason for the failure of clinical chemotherapy. Multiple studies have demonstrated that the formation of MDR in breast cancer is combined with ATP-binding transporters, which are the proteins that can lead to the drug resistance by pumping out chemotherapeutic drugs to reduce their intracellular accumulation. This kind of protein mainly includes P-glycoprotein (Pgp,

Indexed as

Breast cancerbreast cancer resistance protein (BCRP)multidrug resistance (MDR)transcriptional activation

Identifiers

PMID39697732
PMCPMC11651813

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.